BiotechTube
Abram Scientific

Abram Scientific

Cambridge, United States· Est.
abramscientific.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $2.5M

Overview

Founded in 2018 and headquartered in Cambridge, Massachusetts, Abram Scientific is a private, pre-revenue diagnostics company targeting the hemostasis management market. The company is developing a point-of-care platform for coagulation testing, which could enable faster clinical decision-making in settings like surgery, trauma, and anticoagulation clinics. Its technology appears to be in a development stage, with the website indicating updates are coming soon, suggesting it is not yet commercially launched. The company operates in a competitive but high-value market where speed and accuracy in coagulation testing are critical for patient outcomes.

HematologyCoagulation Disorders

Technology Platform

Proprietary point-of-care diagnostic platform for rapid coagulation testing, likely involving microfluidics and proteomic assay technology.

Funding History

1
Total raised:$2.5M
Seed$2.5M

Opportunities

The large and growing market for rapid coagulation testing in surgery, trauma, and anticoagulation therapy management presents a significant opportunity.
The shift towards decentralized, point-of-care testing and the need for faster clinical decision-making to improve outcomes and reduce costs are key market drivers.
Successfully launching a superior product could allow Abram Scientific to capture market share from both central lab and existing POC competitors.

Risk Factors

The company faces intense competition from large, established diagnostics corporations with entrenched products and sales channels.
Technical hurdles in developing a robust, accurate, and user-friendly device, coupled with the significant time and cost of obtaining regulatory clearance (FDA/CE Mark), are major development risks.
Post-approval, securing favorable reimbursement codes and commercial adoption in a cost-conscious healthcare environment are critical commercial risks.

Competitive Landscape

The POC coagulation diagnostics market is competitive, dominated by large players like Roche (CoaguChek), Abbott (i-STAT), and Werfen (Instrumentation Laboratory). These companies offer established devices for tests like PT/INR and aPTT. Abram Scientific would need to differentiate itself through superior speed, a broader test menu, better connectivity, or improved ease of use to gain traction. It may also compete with viscoelastic testing systems like Haemonetics' TEG and Werfen's ROTEM in hospital settings.

More companies in Diagnostics & Precision Medicine →More companies in United States →